Preparation of 12-fluorocamptothecin derivative and application of 12-fluorocamptothecin derivative in anti-tumor aspect

By synthesizing 12-position fluorine-substituted camptothecin compounds, the problem of insufficient inhibitory activity of existing anti-tumor drugs in various tumor cells is solved, and human liver cancer, non-small cell lung cancer, colon cancer, cholangiocarcinoma and breast cancer are achieved. Effective inhibition of cancer cells, low IC50 value, high purity and application prospects.

CN118894867APending Publication Date: 2024-11-05LANZHOU UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410952103.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing anti-tumor drugs have limited effectiveness in treating a variety of tumor cells, especially inadequate inhibitory activity on human liver cancer, non-small cell lung cancer, colon cancer, cholangiocarcinoma and breast cancer cells, and the metabolic stability and solubility of the drug. Need to improve.

Method used

By synthesizing 12-position fluorine-substituted camptothecin compounds, using starting materials such as 3-fluoro-2-nitrobenzaldehyde, 2-amino-3,5-difluorobenzoic acid, etc., it is reduced by iron powder and p-toluene 12-fluorocamptothecin compounds were prepared by sulfonic acid catalysis and other steps to improve their inhibitory activity on a variety of tumor cells.

Benefits of technology

12-fluorocamptothecin compounds showed broad-spectrum anti-tumor activity, and their inhibitory effects on human liver cancer, non-small cell lung cancer, colon cancer, cholangiocarcinoma and breast cancer cells were significantly better than irinotecan, with low IC50 value and Higher purity and application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894867A_ABST
    Figure CN118894867A_ABST
Patent Text Reader

Abstract

The invention relates to preparation of a 12-fluorocamptothecin compound and application of the 12-fluorocamptothecin compound in antitumor drugs. The structural formula of the compound is shown in the specification. In-vitro anti-tumor activity screening results show that the 12-fluorocamptothecin compound has broad-spectrum anti-tumor activity, and shows relatively strong inhibitory activity on human liver cancer cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human bile duct cancer cells (QBC939) and human breast cancer cells (MCF-7). The compound 12-fluorocamptothecin I, the compound 7-ethyl-12-fluorocamptothecin II and the compound 10, 12-difluorocamptothecin III show a relatively strong inhibition effect on the detected five tumor cell lines, and the IC50 values of the compound 12-fluorocamptothecin I, the compound 7-ethyl-12-fluorocamptothecin II and the compound 10, 12-difluorocamptothecin III are respectively 1.325 to 16.807 mu M, 0.261 to 9.251 mu M and 2.502 to 14.226 mu M, which are obviously superior to those of a contrast drug irinotecan. Wherein the compounds I, II and III show the strongest inhibitory activity on an MCF-7 cell line, and the IC50 values of the compounds I, II and III are respectively 1.325 + / -0.077, 0.261 + / -0.038 [mu] M and 2.534 + / -0.287 [mu] M. Therefore, the 12-fluorocamptothecin compound is expected to be developed into a novel antitumor drug. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of natural drug chemistry and relates to the preparation of a 12-fluorine-substituted camptothecin compound and its use in anti-tumor. Background Art

[0002] Fluorination is a widely used drug design strategy. The advantages of fluorinated drugs are mainly reflected in the following four aspects: (1) Due to the high electron affinity of fluorine, the effect on the molecular structure may lead to stronger interactions and enhance the binding ability of drugs to targets; (2) Fluorinated compounds are generally resistant to metabolic enzymes, which improves the metabolic stability of drugs and prolongs their half-life in the body, thereby reducing the frequency of medication; (3) The introduction of fluorine atoms helps to improve the solubility of drugs, thereby improving their oral absorption; (4) The presence of fluorine atoms can change the distribution characteristics of drugs, allowing them to better cross tissue barriers and increase the concentration of drugs in target tissues. According to statistics, about 15%-20% of the new drugs launched each year are organic fluorine compounds. Fluorinated varieties have a very high status in new drug development, especially fluorinated heterocyclic compounds, which are the focus of new drug development. Therefore, the rational use of fluorination strategies is conducive to the discovery of lead compounds and further structural optimization.

[0003] Camptothecin is a quinoline alkaloid isolated from the plant Camptotheca acuminata of the Davidiaceae family. It is a topoisomerase I inhibitor. Due to its strong anti-tumor activity both in vivo and in vitro, the development of low-toxic and highly effective drug molecules based on the camptothecin nucleus has become a research hotspot. To date, camptothecin drugs such as irinotecan, topotecan, and belotecan have been approved for marketing for tumor treatment. The structure-activity relationship of camptothecin shows that modification of the A ring can significantly affect its anti-tumor activity, which is one of the best strategies for further developing new highly active anti-tumor drugs.

[0004] Therefore, we used camptothecin as the lead structure to synthesize a 12-fluorocamptothecin derivative and tested its inhibitory activity against a variety of tumor cells. The experimental results showed that the 12-fluorocamptothecin derivative has a broad spectrum of anti-tumor activity, and its in vitro inhibitory activity against a variety of tumor cells is better than that of irinotecan, and can be developed as a new type of anti-tumor drug. Summary of the invention

[0005] The present invention provides a method for preparing a 12-fluorocamptothecin compound and its use in anti-tumor treatment

[0006] The structural formula of the 12-fluorocamptothecin compound of the present invention is as follows:

[0007]

[0008] The preparation method of 12-fluorocamptothecin compounds of the present invention is carried out according to the following chemical formula 1 and chemical formula 2:

[0009]

[0010] 3-Fluoro-2-nitrobenzaldehyde is used as a starting material, and iron powder, hydrochloric acid and ethanol are reacted under heating reflux conditions to generate 2-amino-3-fluorobenzaldehyde (compound IV); then compound IV and compound V are reacted in toluene solvent under heating reflux conditions overnight with the catalysis of p-toluenesulfonic acid to obtain the target product 12-fluorocamptothecin I; finally, compound I is reacted with n-propionaldehyde to obtain the final product 7-ethyl-12-fluorocamptothecin II.

[0011]

[0012] Chemical formula 2

[0013] Using 2-amino-3,5-difluorobenzoic acid as the starting material, (2-amino-3,5-difluorophenyl)methanol (Compound VI) is obtained by reduction with lithium aluminum hydride; using manganese dioxide as an oxidant, Compound VI is oxidized to 2-amino-3,5-difluorobenzaldehyde (Compound VII); using p-toluenesulfonic acid as a catalyst, Compound VII and Compound V are heated and refluxed overnight in a toluene solution to obtain the target product 10,12-difluorocamptothecin III.

[0014] The present invention relates to a 12-fluorocamptothecin compound that can play a role in the preparation of anti-tumor drugs, and more specifically, can be used in the preparation of drugs for treating human liver cancer, non-small cell lung cancer, colon cancer, bile duct cancer, and breast cancer. The results of in vitro anti-tumor activity screening show that 12-fluorocamptothecin compounds have a broad spectrum of anti-tumor activity and show strong inhibitory activity against human liver cancer cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human bile duct cancer cells (QBC939), and human breast cancer cells (MCF-7). Compounds 12-fluorocamptothecin I, 7-ethyl-12-fluorocamptothecin II, and 10,12-difluorocamptothecin III all showed strong inhibitory effects on the five tumor cell lines tested, with IC 50 The values ​​were 1.325-16.807 μM, 0.261-9.251 μM and 2.502-14.226 μM, respectively, which were significantly better than the control drug irinotecan. Among them, compounds I, II and III showed the strongest inhibitory activity against the MCF-7 cell line, IC 50 The values ​​were 1.325±0.077, 0.261±0.038 μM and 2.534±0.287 μM, respectively.

[0015] Therefore, the 12-fluorocamptothecin compounds of the present invention can be used to prepare anti-tumor drugs, and have novel structures, cheap and available raw materials, high product purity, and exhibit strong inhibitory effects on the proliferation of various tumor cell lines, and have good application prospects.

[0016] The above contents of the present invention are further described in detail below through specific implementation modes, but this should not be construed as limiting the present invention. DETAILED DESCRIPTION

[0017] In order to better understand the present invention, the above contents of the present invention are further described in detail below through specific implementation methods. The experimental methods described in the following examples are conventional methods unless otherwise specified.

[0018] Example 1: Synthesis of Target Compound I

[0019] The synthesis method of compound I of the present invention is carried out according to chemical formula 3:

[0020]

[0021] Synthesis of compound IV: 3-Fluoro-2-nitrobenzaldehyde (2.0 mmol) was dissolved in ethanol (5.7 mL) and the solution was stirred for about 1 minute. Iron powder (6.0 mmol) and dilute hydrochloric acid (0.3 mmol) were added to the stirred solution. The reaction was heated to reflux for 1 hour, after which all the starting materials were reduced. The reaction was cooled to room temperature and stirred for 0.5 hour. The cooled solution was diluted with ethyl acetate (16.5 ml) and stirred for 5 minutes, then filtered through a short diatomaceous earth plug. The filtrate was concentrated to remove the solvent. The crude product was purified by column chromatography to obtain IV as a yellow solid.

[0022] Synthesis of target compound I: Compound V (21.9 mmol) and compound IV (35.1 mmol) were dissolved in toluene solution (10 ml), and water was removed by a water separator under heating reflux for 30 min, and then P-TSA (6.6 mmol) was added, and the reaction was continued overnight. After the reaction was completed, the solvent was removed by vacuum concentration, and the organic layer was extracted with dichloromethane and saturated NaCl solution, and the organic layer was concentrated to dryness under reduced pressure. The crude product was purified by chromatographic column to obtain the target compound 12-fluorocamptothecin I.

[0023] The test data of the product obtained by the reaction are as follows: yield: 65%; yellow solid; 1HNMR(400MHz,CHLOROFORM-D)δ8.40(s,1H),7.72(d,J=18.1Hz,2H),7.62–7.44(m,2H),5.69(dd,J=29.3,16. 8Hz, 1H), 5.33–5.18 (m, 3H), 3.76 (s, 1H), 1.96–1.76 (m, 2H), 1.03 (t, J = 7.4Hz, 3H).; ESI-MSm / z: 367.1[M+H] + .

[0024] Example 2: Synthesis of target compound II

[0025] The synthesis method of compound II of the present invention is carried out according to chemical formula 4:

[0026]

[0027] Dissolve 12-fluorocamptothecin (0.1mmol) in 10.41mL of glacial acetic acid, slowly add 2.6mL of 98% sulfuric acid at 5-10℃, stir until bright yellow, and obtain 12-fluorocamptothecin solution. Add FeSO4·7H2O (0.12mmol) and 13mL of deionized water to another reaction bottle, stir to dissolve; add the above 12-fluorocamptothecin solution at about 2℃, stir evenly, then add freshly distilled propionaldehyde (0.5mmol), stir for a while, slowly add 30% H2O2 (0.5mmol), stir and react for 45min. Pour into appropriate amount of ice water, filter, extract the filtrate with dichloromethane, concentrate the extract to dryness under reduced pressure, and purify the crude product by chromatographic column to obtain the final product 7-ethyl-12-fluorocamptothecin II.

[0028] The test data of the product obtained by the reaction are as follows: yield: 58%; yellow solid; 1 HNMR(400MHz,CHLOROFORM-D)δ7.88(d,J=8.4Hz,1H),7.70(s,1H),7.58(d,J=5.1Hz,1H),7.46(dd,J=10.3,7.7Hz,1H),5.73(d,J=16.2Hz,1H) ,5.33–5.22(m,3H),3.76(s,1H),3.25–3.14(m,2H),1.96–1.80(m,2H),1.40(t,J=7.6Hz,3H),1.02(t,J=7.4Hz,3H).;ESI-MSm / z:395.1[M+H] + .

[0029] Example 3: Synthesis of target compound III

[0030] The synthesis method of compound III of the present invention is carried out according to chemical formula 2:

[0031]

[0032] Synthesis of compound VI: 2-amino-3,5-difluorobenzoic acid (5.78 mmol) was dissolved in tetrahydrofuran (30 ml), cooled to 0 ° C under nitrogen protection, and lithium aluminum hydride (8.7 mmol) was slowly added dropwise within 30 minutes. The reaction solution was first stirred at 0 ° C for 1 hour, and then stirred at room temperature for 18 hours. After the reaction was complete, it was transferred to an ice bath, quenched with ice water, and filtered through diatomaceous earth. The filtrate was extracted with ethyl acetate and saturated brine, and the organic phase was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by chromatographic column to obtain white solid VI (yield: 66%).

[0033] Synthesis of compound VII: Compound VI (3.56 mmol) was dissolved in anhydrous dichloromethane (10 ml), active manganese dioxide (7.13 mmol) was added, and the reaction solution was stirred at 80°C for 4 hours. After the reaction was complete, it was cooled to room temperature and filtered through diatomaceous earth. The filtrate was concentrated and the crude product was purified by chromatographic column to obtain yellow solid VII (yield: 49%).

[0034] Synthesis of target compound III: Compound VII (21.9 mmol) and compound V (35.1 mmol) were dissolved in toluene solution (10 ml), and water was removed by a water separator under heating reflux for 30 min, and then P-TSA (6.6 mmol) was added, and the reaction was continued overnight. After the reaction was completed, the solvent was removed by vacuum concentration, and the organic layer was extracted with dichloromethane and saturated brine, and the organic layer was concentrated to dryness under reduced pressure. The crude product was purified by chromatographic column to obtain the target compound 10,12-difluorocamptothecin III.

[0035] The test data of the product obtained by the reaction are as follows: yield: 53%; yellow solid; 1 HNMR(400MHz,CHLOROFORM-D)δ8.30(s,1H),7.66(s,1H),7.34–7.27(m,2H),5.64(dd,J=39.7,16.7Hz,1H ),5.24(d,J=18.3Hz,3H),3.72(s,1H),1.88–1.71(m,2H),0.97(t,J=7.4Hz,3H).;ESI-MSm / z:385.1[M+H] + Example 4: Test methods and results of antitumor activity of compounds I, II and III

[0036] The standard MTT method was used for in vitro antitumor test. Irinotecan was used as the positive control drug to test the inhibitory activity of target compounds I, II and III against human liver cancer cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human cholangiocarcinoma cells (QBC939), and human breast cancer cells (MCF-7). The compound was dissolved in DMSO to prepare a mother solution with a concentration of 10mM, and diluted to a suitable concentration with different culture media. The DMSO concentration in the dilution should be less than 0.01% (v / v) to reduce the toxicity of DMSO to cells and reduce the test error. Tumor cells of different cell lines were cultured in RPMI-1640 or DMEM high-glucose medium containing 10% fetal bovine serum (FBS), and various cancer cells growing logarithmically were collected, digested with trypsin / EDTA digestion solution and prepared into a suitable cell suspension. Add 100uL of cell suspension to a 96-well plate (usually 5000 cells per well) and place in a 37°C incubator containing 5% CO2 for 24 hours. Then add solutions of the compound to be tested at different concentrations. After 48 hours of culture, discard the old culture medium and wash the cells twice with PBS. Add 25uLMTT (5mg / mL) of fresh culture medium and continue to culture for 4 hours. Thereafter, discard the culture medium and add 200uLDMSO, shake on a shaker for 15 minutes, and wait for the formazan to completely dissolve. Finally, measure the absorbance at 490nm using an enzyme reader and calculate the IC 50 All experiments were performed in three parallel groups or repeated three times. The results of the cytotoxic activity tests of compounds I, II and III are shown in Table 1.

[0037] Table 1 In vitro cytotoxic activity of compounds I, II and III

[0038]

[0039] Note: (1) Screening method: standard MTT colorimetric method; (2) Action time: 48 hours; (3) Compounds I, II and III are the products obtained in the above Examples 1-3.

[0040] The results of in vitro cytotoxic activity screening showed that 12-fluorocamptothecin compounds have a broad spectrum of anti-tumor activity, and showed strong inhibitory activity against human liver cancer cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human cholangiocarcinoma cells (QBC939), and human breast cancer cells (MCF-7). Compounds 12-fluorocamptothecin I, 7-ethyl-12-fluorocamptothecin II, and 10,12-difluorocamptothecin III all showed strong inhibitory effects on the five tumor cell lines tested, with IC 50The values ​​were 1.325-16.807 μM, 0.261-9.251 μM and 2.502-14.226 μM, respectively, which were significantly better than the control drug irinotecan. Among them, compounds I, II and III showed the strongest inhibitory activity against the MCF-7 cell line, IC 50 The values ​​were 1.325±0.077, 0.261±0.038μM and 2.534±0.287μM, respectively. Therefore, 12-fluorocamptothecin compounds are expected to be developed into a new type of anti-tumor drug.

Claims

1. A camptothecin compound, such as 12-fluorocamptothecin compounds I, II and III as shown in the formula.

2. A method for preparing a 12-fluorocamptothecin compound according to claim 1: 3-Fluoro-2-nitrobenzaldehyde is used as a starting material, and iron powder, hydrochloric acid and ethanol are reacted under heating reflux conditions to generate 2-amino-3-fluorobenzaldehyde (compound IV); then compound IV and compound V are reacted in toluene solvent under heating reflux conditions overnight with the catalysis of p-toluenesulfonic acid to obtain the target product 12-fluorocamptothecin I; finally, compound I is reacted with n-propionaldehyde to obtain the final product 7-ethyl-12-fluorocamptothecin II. Using 2-amino-3,5-difluorobenzoic acid as the starting material, (2-amino-3,5-difluorophenyl)methanol (Compound VI) is obtained by reduction with lithium aluminum hydride; using manganese dioxide as an oxidant, Compound VI is oxidized to 2-amino-3,5-difluorobenzaldehyde (Compound VII); using p-toluenesulfonic acid as a catalyst, Compound VII and Compound V are heated and refluxed overnight in a toluene solution to obtain the target product 10,12-difluorocamptothecin III.

3. Use of a 12-fluorocamptothecin compound according to claim 1 in the preparation of a drug for treating human liver cancer (HepG2).

4. Use of a 12-fluorocamptothecin compound according to claim 1 in the preparation of a medicament for treating human non-small cell lung cancer (A549).

5. Use of a 12-fluorocamptothecin compound according to claim 1 in the preparation of a drug for treating human colon cancer (SW480).

6. Use of a 12-fluorocamptothecin compound according to claim 1 in the preparation of a drug for treating human bile duct cancer (QBC939).

7. Use of a 12-fluorocamptothecin compound according to claim 1 in the preparation of a drug for treating human breast cancer (MCF-7).

Citation Information

Patent Citations

  • 10-fluorocamptothecin derivatives, and preparation method and application thereof

    CN105884789A

  • Quinolin-2-one derivatives

    CN108473485A

  • Preparation of 9-fluorocamptothecin derivative and application of 9-fluorocamptothecin derivative in antitumor aspect

    CN113880855A

  • Preparation of 11-fluorocamptothecin derivative and application of 11-fluorocamptothecin derivative in anti-tumor aspect

    CN118239956A

  • Camptothecin derivatives

    US5061800A